RFK Jr. to Reinstate 20% of HHS Staff Laid off After DOGE Errors
European Stocks Poised for Earnings Surprises in April
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Ahead of Employment Situation Report
AstraZeneca PLC's (LON:AZN) Stock Has Fared Decently: Is the Market Following Strong Financials?
AstraZeneca Scores EU Approvals for Two Key Cancer Drugs
AstraZeneca, Daiichi Sankyo Obtain EU Approval for Enhertu as Breast Cancer Treatment
AstraZeneca's Imfinzi Regimen Wins EU Approval for Resectable Lung Cancer
Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025
European Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
AstraZeneca (AZN.US) has submitted a new indication for "Benralizumab" for market approval in China.
AstraZeneca (AZN.US) has applied for the market approval of the new indication for "Breztri aerosol" in China.
Today's Pre-Market Movers and Top Ratings | TSLA, AAPL, AZN and More
Pharma Stocks up on US Tariff Exemptions but Analyst Flags a $46B Import Cost Risk
Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)
BofA Lifts AstraZeneca Earnings Forecast Amid Busy Pipeline Path Ahead
Buzz-GSK, AstraZeneca Rise as US Reciprocal Tariffs Exclude Pharma Sector
U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk
AstraZeneca Put Volume Heavy and Directionally Bearish
SA Asks: How Will Changes at FDA Impact Vaccine Makers?
AstraZeneca (AZN.US) has received approval for clinical trials of a new triple-antibody drug in China, intended for the treatment of systemic lupus erythematosus and others.
This product was first approved for clinical use in China in October 2024, indicated for relapsed or refractory B-cell malignancies.
Peering Into AstraZeneca's Recent Short Interest